Our Custom Antisense Oligonucleotide (ASO) Synthesis services support biotechnology teams, pharmaceutical research groups, CROs, academic laboratories, and RNA-focused discovery programs requiring sequence-specific oligonucleotides for RNA modulation studies. ASOs can be engineered to operate through different mechanisms, including RNase H-dependent RNA degradation and steric blocking of RNA processing, translation, or molecular interactions. Successful ASO synthesis therefore depends not only on producing the requested sequence, but also on matching sequence architecture, backbone chemistry, sugar modification, purification strategy, and analytical requirements to the intended research mechanism.
We provide project-specific support across ASO sequence review, gapmer and steric-blocking architectures, phosphorothioate incorporation, 2'-O-methyl, 2'-O-methoxyethyl and LNA-containing constructs, custom conjugation, purification, and analytical characterization. Projects can be configured for individual candidates, comparative chemistry studies, or multi-sequence screening programs, helping research teams obtain well-defined ASO materials with chemistry and quality attributes aligned to downstream experiments.
Mechanism and Chemistry Alignment: An ASO intended to recruit RNase H requires a different architecture from a fully modified steric-blocking oligonucleotide. We help evaluate whether a DNA-containing gapmer, modified mixmer, or steric-blocking design better matches the intended RNA interaction so that chemical stabilization does not unintentionally interfere with the required mechanism.
Target Accessibility and Sequence Selection: Complementarity alone does not guarantee useful target engagement. RNA secondary structure, transcript isoforms, local sequence composition, self-complementarity, GC distribution, and potential cross-hybridization can affect candidate behavior. Sequence review helps prioritize practical ASO designs before synthesis and screening.
Modification Density and Synthesis Complexity: Phosphorothioate linkages, LNA, 2'-O-methyl, 2'-MOE, terminal groups, and conjugates can improve selected ASO properties but also increase synthesis and purification complexity. Modification placement must be planned together with coupling efficiency, deprotection requirements, hydrophobicity, and downstream analytical behavior.
Purity Versus Recovery: Highly modified ASOs can generate closely related truncated or chemically altered species that are difficult to separate. Purification method selection therefore needs to consider sequence length, modification pattern, target purity, required quantity, and whether the material is intended for screening, biochemical assays, or cell-based research.
Delivery and Handling Constraints: An ASO that performs well in a hybridization assay may still face uptake, adsorption, solubility, or formulation challenges in cell-based workflows. Conjugation and delivery considerations can be incorporated early through our oligonucleotide conjugation services and RNA delivery system support.
Our ASO synthesis services are structured around the decisions that most strongly affect experimental performance: target mechanism, sequence architecture, modification pattern, synthesis feasibility, purification, analytical verification, and downstream format. Customers can submit a finalized ASO sequence or engage our team for chemistry and manufacturability review before synthesis.
Individual candidates, chemically diverse comparison sets, and screening libraries can be supported through coordinated custom oligonucleotide synthesis, modification, purification, characterization, and conjugation workflows.
ASO chemistry should be selected according to the required biological mechanism rather than modification strength alone. The matrix below summarizes common architecture choices and the technical questions that should be resolved before custom synthesis.
| ASO Format | Primary Mechanism | Typical Chemistry Logic | Critical Design Questions | Research Fit |
| DNA/PS ASO | RNase H-compatible RNA targeting | DNA sequence with partial or extensive phosphorothioate linkage incorporation | Target accessibility, nuclease resistance, PS placement, sequence specificity, purification requirement | Initial mechanism studies and comparative antisense experiments |
| 2'-OMe Gapmer | RNase H recruitment through a central DNA region | DNA gap flanked by 2'-O-methyl-modified wings, frequently combined with PS linkages | DNA gap length, wing length, modification density, affinity, transcript accessibility | RNA knockdown screening and chemistry optimization studies |
| 2'-MOE Gapmer | RNase H-mediated target RNA cleavage | Central DNA gap with 2'-MOE-containing wings and project-defined backbone chemistry | Wing-to-gap balance, target affinity, sequence composition, synthesis complexity | Mechanistic antisense research and optimized candidate comparison |
| LNA Gapmer | RNase H recruitment with high-affinity modified wings | DNA gap flanked by selected LNA residues, commonly combined with nuclease-resistant backbone design | LNA number and position, duplex affinity, sequence selectivity, self-complementarity | Shorter high-affinity ASO designs and difficult RNA targets |
| Fully Modified ASO | Steric blocking rather than RNase H cleavage | Modified sugar chemistry distributed throughout the oligonucleotide | Binding site function, target occupancy, affinity, nuclease resistance, uptake strategy | Splice modulation, translation blocking, and RNA-interaction studies |
| Conjugated ASO | Mechanism defined by ASO core with added targeting, uptake, or detection functionality | ASO linked to peptide, lipid, carbohydrate, fluorophore, affinity tag, or other functional moiety | Attachment site, linker length, hydrophobicity, purification behavior, retained hybridization | Delivery feasibility, uptake studies, imaging, localization, and target-engagement research |
Modified ASOs can contain synthesis-related truncated sequences, incompletely modified products, and closely related chemical species. Purification and analytical methods should therefore be selected according to the ASO architecture and the decisions the material will support downstream.
| Evaluation Area | Primary Question | Applicable Approach | When It Matters Most | Customer Value |
| Crude Profile Review | Does the synthesis mixture show acceptable full-length product formation? | Chromatographic profile assessment and synthesis review | Highly modified sequences, difficult coupling patterns, or complex conjugates | Guides purification strategy before material recovery is committed |
| Preparative Purification | Which method best separates full-length ASO from related impurities? | Reverse-phase HPLC, ion-exchange approaches, PAGE, or other fit-for-purpose purification | Screening candidates requiring defined purity and complex modified ASOs | Balances purity, recovery, chemistry, and downstream experimental needs |
| Identity Confirmation | Is the isolated material consistent with the intended molecular composition? | Mass spectrometric confirmation selected according to ASO chemistry | Modified, conjugated, or sequence-critical research materials | Provides direct confirmation of product identity |
| Purity Assessment | What proportion of the analytical profile corresponds to the principal ASO product? | Analytical HPLC, UPLC, ion-exchange, or electrophoretic analysis as appropriate | Comparative screening and downstream quantitative studies | Helps users judge whether batches are suitable for intended experiments |
| Quantity Determination | How much ASO material is available for experimental use? | UV absorbance-based quantification or project-appropriate measurement | Dose-response, multi-assay, and library screening workflows | Supports reproducible experimental setup and material allocation |
| Conjugate Review | Has attachment of the functional moiety changed purity or product behavior? | Comparative chromatographic and mass-based characterization | Peptide-, lipid-, carbohydrate-, or reporter-conjugated ASOs | Confirms that the final construct, not only the parent ASO, is being evaluated |
| Final Documentation | Are sequence, chemistry, purification, and analytical results clearly traceable? | Project-specific synthesis and QC summary | Cross-team transfer, comparative studies, and repeat synthesis | Simplifies internal review and future project continuation |
Our workflow connects biological intent with practical oligonucleotide chemistry. Each stage is designed to identify sequence or modification risks early, define appropriate purification and QC requirements, and provide research teams with clearly specified ASO material for downstream evaluation.
We review the target RNA, transcript region, experimental objective, desired mechanism, preferred candidate number, and downstream assay format. This first step distinguishes RNase H-dependent projects from steric-blocking, splice-interference, or other RNA-binding strategies before chemistry is selected.
Candidate sequences are assessed for composition, target context, self-complementarity, modification requirements, and synthesis feasibility. Gap, wing, backbone, terminal, and conjugation choices are then aligned with the intended ASO mechanism and research conditions.
The final sequence notation, modification map, synthesis quantity, purification approach, analytical package, delivery format, and any library organization requirements are confirmed. This reduces ambiguity before solid-phase synthesis begins.
The ASO is assembled using chemistry appropriate to the requested nucleotide and backbone composition, followed by cleavage, deprotection, and purification. Purification conditions are selected with attention to sequence length, PS content, hydrophobic modifications, and conjugation status.
Purified material is evaluated using the agreed analytical package. Identity, purity, quantity, and conjugate integrity are reviewed as applicable, and unexpected analytical features can be assessed before final project release.
Final ASO material and supporting documentation are supplied in the agreed project format. Our team can also assist with repeat synthesis, additional candidate libraries, chemistry comparisons, conjugation planning, or oligonucleotide stability testing for subsequent research.
ASO projects benefit from a synthesis partner that understands how target biology, oligonucleotide chemistry, purification, and analytical behavior interact. Our service model is designed to help research teams make technically defensible choices while keeping sequence architecture and material requirements flexible.
Custom ASOs can be adapted to multiple RNA research questions by changing sequence, chemical architecture, and mode of action. Our synthesis workflows support individual mechanistic studies as well as broader screening and optimization programs.
Whether your project requires a single modified antisense oligonucleotide, an RNase H-active gapmer, a steric-blocking construct, a conjugated ASO, or a multi-sequence screening library, our team can help translate the research objective into a practical synthesis specification. We support sequence and chemistry review, custom synthesis, purification, analytical verification, library production, and follow-on optimization so that each ASO is developed around its intended experimental role rather than treated as a standard oligonucleotide order. Contact us to discuss your target, sequence requirements, modification strategy, quantity, and analytical expectations for a customized ASO synthesis plan.
Custom ASO synthesis produces sequence-specific oligonucleotides designed to bind selected RNA targets. The sequence, backbone, sugar chemistry, terminal groups, purification, and analytical package can be configured for the intended research mechanism.
A gapmer contains a DNA region that can support RNase H-mediated cleavage of complementary RNA, typically with modified nucleotides at the ends. A steric-blocking ASO binds RNA without relying on RNase H and instead interferes with RNA processing or molecular interactions.
Common options include phosphorothioate linkages, 2'-O-methyl, 2'-MOE, LNA, 2'-fluoro, modified bases, terminal groups, spacers, fluorescent labels, and selected conjugates. Feasibility depends on the sequence and modification combination.
Phosphorothioate linkages can increase resistance to nuclease degradation. Their number and position should be considered together with target mechanism, binding behavior, synthesis complexity, and downstream experimental requirements.
Many common 2'-modified ASO architectures are not directly RNase H competent when the complementary region is fully modified. RNase H-active gapmers therefore generally retain a central DNA region while modified nucleotides are positioned in the flanking wings.
Loading ......
